Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss